Related Experiment Video
Updated: May 16, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
HCV NS5A inhibitors in development
1Division of Gastroenterology and Hepatology, University of Michigan Health System, University of Michigan, Ann Arbor, 48109, USA. aslok@umich.edu
Abstract:
NS5A protein plays a key role in hepatitis C virus (HCV) replication. Daclatasvir (DCV, BMS-790052) is a first-in-class inhibitor of the HCV NS5A replication complex with potent antiviral activity but a low barrier to resistance. DCV as triple therapy in combination with pegylated interferon and ribavirin resulted in a high rate of early virologic response in treatment-naïve patients with genotype 1 infection; as quadruple therapy in combination with asunaprevir (BMS-650032, NS3 protease inhibitor), pegylated interferon, and ribavirin, it resulted in a high rate of sustained virologic response in genotype 1 prior null responders.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Viral Hepatitis I: Introduction
Subviral Agents
Cytomegalovirus Disease
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

